Key Highlights
- Shares of NVS declined roughly 2% during pre-market trading following a first-quarter earnings disappointment
- Revenue reached $13.11B, falling short of the $13.40B Wall Street estimate and representing a 1% year-over-year decline
- Entresto revenue plummeted 42% to $1.31B following U.S. patent loss and generic market entry
- Core earnings per share decreased to $1.99 from $2.28; core operating income declined 12% to $4.9B
- CEO Vas Narasimhan cautioned that the U.S. “most favored nation” pricing framework could restrict patient access to innovative therapies in Europe and Japan within the next 18 months
Novartis kicked off 2026 on a challenging note, delivering first-quarter financial results that fell below expectations on both the revenue and profitability fronts as generic competition intensified beyond market projections.
Revenue totaled $13.11 billion, missing the $13.40 billion Wall Street consensus estimate. Core operating income tumbled 12% to $4.9 billion, which also trailed the approximately $5.1 billion consensus compiled by Visible Alpha.
The primary driver behind the underperformance was Entresto, the pharmaceutical giant’s blockbuster cardiovascular medication. Revenue from this treatment collapsed 42% to $1.31 billion following the expiration of U.S. patent protection and subsequent generic market penetration. The Street had anticipated $1.37 billion.
Entresto represented 14% of consolidated revenue during the previous fiscal year, marking this as among the most significant patent cliff challenges in the company’s recent operating history. CEO Vas Narasimhan has characterized it as the most substantial patent expiration Novartis has encountered in twenty years.
The erosion extends beyond Entresto. Promacta, used for blood disorders, and Tasigna, a leukemia therapy, are similarly confronting generic competition, compounding the pressure on overall revenue growth.
Core earnings per share contracted to $1.99, down from $2.28 during the comparable prior-year period. Operating income decreased 9% while net income slid 13%, driven by both the revenue shortfall and elevated research and development expenditures.
CFO Mukul Mehta informed media that the performance aligned with internal projections. He indicated the organization anticipates “growth to return back to our P&L in the second half of this year.”
Novartis maintained its full-year outlook, citing a robust development pipeline and continuing product launches. The organization projects approximately $4 billion in revenue erosion this year stemming from generic competition affecting Entresto, Promacta, and Tasigna.
CEO Raises Alarm on MFN Policy Implications
Beyond the quarterly financials, CEO Narasimhan leveraged the earnings release to voice apprehensions regarding U.S. pharmaceutical pricing regulations, particularly the “most favored nation” framework.
The MFN approach links U.S. medication prices to those paid in other developed nations. Narasimhan cautioned the ramifications would extend internationally, stating “the reality of MFN is going to set in in the next 18 months.”
He indicated Novartis is urging Europe and Japan to reconsider their pharmaceutical pricing and reimbursement mechanisms. Absent modifications, he cautioned that “novel medicines might see delayed entry” and patient availability could deteriorate.
Presently, the immediate impact on Novartis remains contained. MFN currently affects approximately 5% to 10% of Medicaid-related revenue. However, Narasimhan views the framework as permanent. “I don’t see it disappearing in the U.S.,” he stated.
His observations mirror concerns from industry counterparts. Roche and AstraZeneca have similarly identified Europe’s pricing infrastructure as an escalating threat to future medication accessibility.
Analysts Maintain Cautious Optimism
Notwithstanding the quarterly miss, Wall Street maintains a generally favorable stance on the equity. Novartis carries a Moderate Buy consensus rating derived from six analyst assessments.
The consensus price target stands at $169.86, suggesting approximately 17% appreciation potential from present trading levels.
Entresto will confront patent expirations in Europe beginning in November, which will intensify revenue headwinds during the latter half of the year.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
